

JPW

Dkt. 56613-A/JPW/AJM/JCS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ann Marie Schmidt, et al.
Serial No.: 10/783,635 Group Art Unit: 1641
Filed : February 20, 2004
For : METHOD FOR DETERMINING WHETHER A COMPOUND IS CAPABLE
OF INHIBITING THE INTERACTION OF A PEPTIDE WITH RAGE

1185 Avenue of the Americas
New York, New York 10036
April 27, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the enclosed Supplementary Partial European Search Report issued by the European Patent Office on February 17, 2005 in connection with related European Patent Application No. 99954753.2. 37 C.F.R. §1.97(b) provides that an Information Disclosure Statement will be considered if it is filed before the mailing of the first Office Action on the merits. Accordingly, this Information Disclosure Statement is being timely filed.

This Information Disclosure Statement is submitted as a supplement to the Information Disclosure Statement filed October 14, 2004. Applicants direct the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit 1**.

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 2

1. February 17, 2005 Communication from the European Patent Office forwarding a Supplementary Partial European Search Report in connection with European Patent Application No. 99954753.2, published August 29, 2001 (**Exhibit 2**)
2. Dyer, et al., "The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly," BR J. Clin. Pharmac. 38: 205-212 (1994) (**Exhibit 3**);
3. Nurse, "A reappraisal of oral quinine in discoid lupus erythematosus," Aust. J. Derm. 13: 55-59 (1972) (**Exhibit 4**);
4. RU 2092195C, Nizhegorod Skin Veneral Res. Inst./Potentsial Res. Tech. Centre, October 10, 1997 (**Exhibit 5**);
5. Oku, et al., "Effects of oral and parenteral quinine of rats with ventromedial hypothalamic knife-cut obesity," Metabolism 33: 538-544 (1984) (**Exhibit 6**);
6. Santos, et al., "A study of the anti-pyretic effect of quinine, an alkaloid effective against cerebral malaria, on fever indicated by bacterial endotoxin and yeast in rats," J. Pharm. Pharmacol. 50: 225-229 (1998) (**Exhibit 7**);
7. Smith-Kline Beecham Corporation, International Patent Application No. PCT/US96/14347, published March 13, 1997 (**Exhibit 8**);
8. Yamamoto, et al., "Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 3

cells through the induction of platelet-derived growth factors," Biochemical and Biophysical Research Communications 222: 700-705 (1996) (**Exhibit 9**); and

9. Rimchala, et al., "Pharmacokinetics of quinine in patients with chronic renal failure," Eur. J. Clin. Pharmacol. 49: 497-501 (1996) (**Exhibit 10**).

Applicants request that the Examiner review the references and make them of record in the subject application.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Applicants: David M. Stern et al.
U.S. Serial No.: 09/374,213
Filed: August 13, 1999
Page 4

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.


Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Alan J. Morrison Date: 4/27/05 Reg.
No. 37,399

U.S. Department of Commerce
Patent and Trademark Office

(Use several sheets if necessary)

Application Number	10/783,635
Filing Date	February 20, 2004
First Named Inventor	Ann Marie Schmidt, et al.
Art Unit	1641
Examiner Name	
Attorney Docket No.	56613-A/JPW/AJM/JCS

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		PCT/US96/14347	3/13/1997	Smith-Kline Beecham Corporation	

DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	10/783,635
	Filing Date	February 20, 2004
	First Named Inventor	Ann Marie Schmidt, et al.
	Art Unit	1641
	Examiner Name	
	Attorney Docket No.	56613-A/JPW/AJM/JCS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 17, 2005 Communication from the European Patent Office forwarding a Supplementary Partial European Search Report in connection with European Patent Application No. 99954753.2, published August 29, 2001	
		Dyer, et al., "The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly," BR J. Clin. Pharmac. 38: 205-212 (1994)	
		Nurse, "A reappraisal of oral quinine in discoid lupus erythematosus," Aust. J. Derm. 13: 55-59 (1972)	
		RU 2092195C, Nizhegorod Skin Veneral Res. Inst./Potentsial Res. Tech. Centre, October 10, 1997	
		Oku, et al., "Effects of oral and parenteral quinine of rats with ventromedial hypothalamic knife-cut obesity," Metabolism 33: 538-544 (1984)	
		Santos, et al., "A study of the anti-pyretic effect of quinine, an alkaloid effective against cerebral malaria, on fever indicated by bacterial endotoxin and yeast in rats," J. Pharm. Pharmacol. 50: 225-229 (1998)	
		Yamamoto, et al., "Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factors," Biochemical and Biophysical Research Communications 222: 700-705 (1996)	
		Rimchala, et al., "Pharmacokinetics of quinine in patients with chronic renal failure," Eur. J. Clin. Pharmacol. 49: 497-501 (1996)	

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.